INTRODUCTION
Respiratory syncytial virus (RSV) is a major cause of acute lower respiratory infection in infants and young children and is a leading cause of infantile bronchiolitis worldwide (1, 2) . In industrialized countries, hRSV accounts for up to 70% of hospitalized bronchiolitis cases (1) (2) (3) . Although the antiviral drugs Palivizumab and Ribavirin have virucidal activity against RSV in vivo, there are no fully satisfactory therapeutic regimens or vaccines (4) (5) (6) . It is estimated that 3% of RSV cases in the United States and 10% of cases worldwide result in hospitalization; the reported number of new cases of lower respiratory infection due to RSV in children under 5 in 2005 was 33.8 million (7, 8) . Thus, there is a need for new therapies for RSV infection.
The host defense activity of the airway epithelium is critical for the continuous inactivation and removal of inhaled microbes from the respiratory tract. While the role of mucociliary clearance and epithelial host defense proteins and peptides in lung immunity is well established, the recognition that airway epithelial cells express an oxidative microbicidal system is recent (9-13; reviewed in 11, 12) . This three-component oxidative system consists of two (10, (13) (14) (15) (16) (17) (18) (19) (20) (21) . Both LPO and SCN -are highly concentrated in the airway surface liquid (ASL). The Duox/LPO/SCN -system generates sufficient OSCN -to eliminate bacteria in vitro and in vivo (13, 22, 23) . In vitro, the substitution of iodide (I -) for SCN -in this system yields hypoiodous acid (H 2 O 2 + I -→ HOI) instead of the physiological product, OSCN - (24) . HOI has potent microbicidal activity against bacteria (23) and viruses (26) , including activity against RSV, whereas OSCNexhibits little antiviral activity (24) . We previously reported that I -is concentrated in the nasal ASL of human subjects following oral I -supplementation using an FDA-approved formulation (24) . However, it was not tested whether I -supplementation also led to high I -concentration in the ASL of lower airways and whether a high Iconcentration in the ASL could affect the severity of respiratory viral infections.
The ovine respiratory tract functionally expresses the Duox/LPO/halide system (23) , is susceptible to human strains of RSV, and develops microscopic lesions similar to those in infants (for review see 27; 28-30) . Some other animal species used to model RSV infection (e.g., mice and rats) lack airway submucosal glands (31) which are the LPO-secreting structures in the airways of larger mammals. Without LPO production in the airways, the Duox/LPO/halide system is not fully functional. Therefore, lambs were used to test the hypothesis that I -supplementation can protect the newborn lung against RSV infection. The life cycle of RSV is restricted to the epithelia of the respiratory tract. Because the Duox/LPO/halide system is dependent upon mature epithelia and submucosal glands that can produce adequate levels of enzymes and halide transport proteins, studies were completed in both newborn and 3-week-old lambs. The concentrations of I -and SCN -in the nasal secretions and serum of lambs were measured after the administration of NaI (1.7 mg/kg body weight, n = 5) or PBS (control, n = 5) via the external jugular vein. Nasal secretions and blood samples were collected at 4 time points: at 0 hour (just before the injection of NaI), 4 h, 12 h, and 36 h. Blood (8 ml) was drawn from the external jugular vein, and serum was collected. Nasal secretions were collect with microsampling probes (Olympus BC-402C) as previously described (24, 32) . Nasal fluid was recovered from the microsampling probes by microcentrifugation. Both serum samples and nasal secretions were diluted in water and analyzed for anion composition using ion-exchange chromatography as described previously (24, 32) .
The above described experimental design was slightly modified to determine the effect of intragastric delivery of KI on the concentrations of I -and SCN -in airway secretions. Briefly, lambs (n = 5) received KI-containing PBS (1.8 mg KI/kg body weight) via an 18 French Foley catheter followed by 6 ml of water flush to clear. Nasal secretions and serum samples were collected at 0 hour (just before the intragastric gavage), 4 h, 12 h, and 36 h. At 4 and 12 hour, one animal/time point was euthanized after the collection of serum and nasal secretions to harvest tracheobronchial secretions as previously described (24, 32) . The remaining 3 animals were euthanized at 36 hours for the collection of tracheobronchial secretions.
Lamb RSV challenge experiments.
Lambs were randomly assigned to 3 groups: the first group was inoculated with RSV, the second group was inoculated with RSV and treated with KI, and the third group was neither inoculated with RSV nor treated with KI. Using this experimental design, a pilot experiment was carried out in which the human pathogen RSV strain A2 was delivered through a fiberoptic bronchoscope (10 8 PFU RSV in 10 ml cell culture medium) into the trachea of newborn lambs (2-3 days of age; n = 5). In this pilot experiment, the KI-treated lambs (n = 5) received 1.8 mg KI/kg body weight in PBS by intragastric gavage 4 hours prior to the inoculation of RSV A2 and daily thereafter.
Control lambs (n = 3) received I -free PBS through via intragastric gavage and sterile cell culture medium (10 ml) through the bronchoscope. In subsequent experiments involving 2-3 day old lambs and 3-week-old lambs, a more pathogenic RSV strain (Memphis 37) (27) was delivered (3.5 x 10 7 PFU) to lambs in 6 ml culture medium using a PARI Sprint TM nebulizer and a cone face mask fitted with a rubber gasket that provided a seal around the mandible and nose. In addition, the dose of KI was increased to 10 mg KI/kg body weight/day. Control lambs received I -free PBS intragastrically(6 ml) via nebulization and additional group of lambs received Dapsone which inhibits lactoperoxidase activity. See online data supplement for additional methods. RESULTS
Airway surface liquid iodide levels after intravenous and intragastric iodide delivery.
To evaluate the extent to which systemic I -administration to lambs affects the ASL concentration of I -, nasal secretions and serum samples were collected from lambs that received sodium iodide (NaI) in PBS intravenously (1.7 mg NaI/kg body weight) or PBS only (negative control). Ion-exchange chromatography analysis of these samples showed that the I -concentration increased in the nasal secretions to ~340 µM at the 4-hour time point, whereas the serum I -concentration only increased to ~14 µM ( Figure 1A and 1B) . By the 36-hour time point, the I -concentration in the nasal secretions returned to near base-line levels. Interestingly, the SCNconcentration decreased in the nasal secretions when the I -concentration reached its peak in the serum (supplemental figure E2) , suggesting that SCN -and I -compete for the same transporters in the airway. Iadministration to humans also leads to a greatly increased [I -] in the nasal ASL (24) . Thus, our data indicate that the upper airway of lambs recapitulates the halide-transporting activity of the human nasal mucosa.
Next, we examined whether intragastric administration of I -also leads to elevated concentration of I -in the secretions of the upper and lower airways. We used intragastric gavage to deliver KI (1.8 mg KI/kg body weight) to lambs. Nasal secretions and serum samples were harvested at 4 time points (0, 4, 12 and 36 hours).
Tracheobronchial secretions were collected immediately after euthanizing lambs at 4, 12, and 36 hours. Analysis of these samples showed that intragastric KI administration led to a more prolonged increase of I -in the serum, nasal secretions, and tracheobronchial secretions than the IV delivery of NaI ( Figure 1) . Furthermore, the upper and lower airway secretions contained similar levels of I -at each time point ( Figure 1C ). These data indicate that intragastric delivery of I -to lambs leads to elevated I -concentration in the ASL of both the lower and upper airways.
Pilot study: Iodide effects human RSV strain A2 in vivo.
A pilot study was completed in order to establish an initial proof-of-principal that I -would have some effect on reducing RSV replication. Lambs received intragastric KI supplementation or control (i.e. I -free) solution 4 hours prior to intratracheal inoculation of hRSV A2 and daily thereafter. The severity of hRSV A2 infection was evaluated 6 days later when the RSV-induced lung lesions are maximal in this model (25, (30) (31) (32) (33) . In the lungs of KI-treated lambs, we found reduced hRSV A2 RNA levels ( Figure 2A ) and a reduction in gross and histological lesions (consolidation score: 2.22 ± 0.9) compared to untreated lambs infected with hRSV A2 (consolidation score: 4.9 ± 0.8) (p<0.05). After 6 days of I -supplementation, treated lambs had significantly increased [I -] in tracheal ASL compared to non-supplemented controls ( Figure 2B ). These findings suggest that I -administration is associated with reduced RSV disease severity.
Iodide effects on RSV M37 infection in newborn (2-3 day-old) lambs. Because the pilot studies demonstrated reductions in both lung lesions and RSV RNA levels, additional studies were completed in 2-3 day-old lambs in order to further investigate the extent to which I -reduces RSV severity in newborn lambs. The virus strain RSV Memphis 37 (M37) was used in these studies because M37 is less laboratory-adapted than RSV A2 and the lung disease caused by M37 is very similar in lambs and human infants.
Effect of KI on clinical parameters, lesions, and bronchoalveolar lavage fluid. There was a significant reduction in the incidence and severity of enhanced expiratory effort (forced expiration) in lambs receiving KI treatment at days 2, 3, 4, 5 and 6 post-inoculation ( Figure 3A ) compared to RSV-inoculated lambs without KI prophylaxis.
Control lambs showed no increased expiratory effort. Among virus-treated lambs, 2/12 KI-treated RSVinoculated lambs exhibited mildly increased expiratory effort whereas 9/12 lambs given RSV without KI treatment had increased expiratory effort that was moderate to marked. There were no significant differences between groups of lambs (RSV M37 without KI treatment; RSV M37 with KI treatment; control) in weight gain, temperature, or respiratory rate. Lung lesions were significantly reduced in KI treated lambs compared to untreated RSV-inoculated lambs ( Figure 3B ). Gross lesions were present in 11/12 of lambs receiving RSV M37 without KI; these were marked in 7/12 and mild in 4/12. In contrast, 2/12 KI-treated lambs receiving RSV M37 had marked gross lesions, 9/12 had mild lesions, and 1/12 had no lesions. To evaluate the effect of KI treatment on the inflammatory cell populations within the lung, BALF differential cell counts were performed. In newborn lambs, no statistically significant differences were detected between groups. However, there was a trend for the RSV-infected lambs that received KI treatment to have an increased proportion of lymphocytes (p = 0.096; ANOVA). Consolidation scores determined by histopathology for lambs inoculated with RSV M37 lacking KI treatment (0.64 ± 0.32) were not significantly altered from lambs treated with KI (0.70 ± 0.29); controls (no RSV; no KI) lacked lesions (0.00 consolidation score). Lambs receiving Dapsone, KI and RSV had significantly increased levels of expiratory effort, gross and histologic lesion scores compared to control and KI-treated lambs (no Dapsone) and increased gross and microscopic lesions compared to M37 alone (no KI or Dapsone) ( Fig.   3A-D) . The findings, demonstrate that KI treatment reduces some, but not all clinical parameters of RSV infection and that inhibition of lactoperoxidase (with Dapsone) eliminates the anti-RSV effects of the Duox/LPO enhanced with KI. Dapsone itself lacks anti-RSV activity (Supplemental Figure E5) .
Effect of KI on RSV replication and cytokines. By immunohistochemistry, RSV viral antigen abundance was significantly reduced in epithelial cells lining both alveoli (Alv) and airways (bronchioles and bronchi, Br) in KItreated lambs compared to RSV-inoculated lambs with no KI treatment ( Figures 3C, 3D, 3E ). Lambs receiving Dapsone, KI and RSV had significantly increased levels of RSV mRNA and antigen compared to control and KItreated lambs (no Dapsone) and also compared to M37 alone (no KI or Dapsone) (Fig. 3C, 3D ). Levels of RSV N gene mRNA, immune and inflammatory gene mRNAs were assessed by RT-qPCR. RSV mRNA levels trended lower in KI-treated lambs but not significantly (supplemental Figure E3) . IL-8 mRNA levels were significantly reduced in KI-treated lambs compared to RSV-inoculated lambs lacking KI (supplemental Figure   E3 ). Also, IFN mRNA levels were significantly higher in KI-treated lambs compared to lambs receiving RSV M37 without KI treatment (supplemental Figure E3 ). Control lambs lacked RSV mRNA and increases/alterations in innate and adaptive immunity genes. The levels of IFNβ, MCP-1α, MIP1α, RANTES, SBD-1, SP-A, TGFβ, and PD-L1 mRNA in KI-treated lambs trended higher compared to lambs inoculated with RSV M37 without KI prophylaxis. In contrast, RNA levels of RSV and mRNA levels of CC10, IL-6, IL-10, IP10, MCP2, MIP1β, SP-D and TNFα trended higher for lambs receiving RSV M37 compared to RSV-inoculated lambs treated with KI. (For more details on the RT-qPCR procedure, see online data supplement). These findings demonstrate that KI treatment is associated with reductions in some parameters of RSV infection.
Iodide effects on RSV M37 infection in 3-week-old lambs.
It is possible that with increased lung maturation, the Duox or LPO enzymes or other components of the Duox/LPO/halide system undergo/exhibit increased expression and function compared to newborn lungs. Therefore, the extent to which KI treatment reduces RSV disease severity in 3-week-old lambs was determined.
Effect of KI on clinical parameters, lesions, and bronchoalveolar lavage fluid.
Lung lesions were less frequent in 3-week-old lambs with KI treatment (8.6 ± 1.9) compared to RSV inoculated lambs lacking KI (4.9 ± 1.6) but this difference was not significant; control animals lacked lesions. Consolidation scores determined by histopathology for 3-week-old lambs inoculated with RSV M37 and lacking KI treatment (1.1 ± 0.6) trended higher than those from lambs treated with KI (0.70 ± 0.7) but lacked statistical significance; controls (no RSV) lacked lesions (0.00 consolidation score). Clinically, there were no significant differences in expiratory effort among control or treatment groups in 3-week-old lambs. There were no significant differences between groups of 3-week-old lambs (RSV M37 without KI treatment; RSV M37 with KI treatment; control) in weight gain, temperature, heart and respiratory rates, and expiratory effort. To evaluate the effect of KI treatment on inflammatory cell populations within the lung, differential cell counts were performed on BALF. In 3-week-old animals, KI treatment significantly reduced the proportion of macrophages within BALF in RSV-infected lambs. No significant differences were detected in the populations of other cells, although there was a trend for the KI treated lambs to have a higher proportion of lymphocytes (p = 0.057) compared with RSV-infected lambs that did not receive treatment ( Figure 4A ). Comparison between the two RSV-infected groups and uninfected controls were not possible in this age group since too few control lamb samples were present.
Effect of KI on RSV replication. RSV titers in BALF were significantly reduced in 3-week-old lambs treated with KI compared to lambs inoculated with RSV lacking KI ( Figure 4B ). Control lambs (receiving no RSV or KI) lacked viral titers. RSV viral antigen abundance determined by immunohistochemistry was significantly reduced in the epithelial cells lining both the airways (bronchi and bronchioles, Br) and alveoli (Alv) in 3-week-old lambs receiving KI compared to RSV-inoculated lambs lacking KI ( Figure 4C ). The levels of RSV nucleoprotein mRNA 9 measured by RT-qPCR were significantly reduced in 3-week-old lambs receiving KI compared to RSVinoculated lambs lacking KI ( Figure 4D ).
Ontologic expression of Duox 1, 2 and Lactoperoxidiase genes in lamb lung.
Because the lung of newborns continues to develop and mature after birth and also because expression of Duox1, Duox2, and LPO is essential for converting I -into hypoiodous acid, the extent of expression of these genes during ontogeny was measured by RT-qPCR using total RNA isolated from lung tissues collected from lambs at various time points during gestation and compared to adult expression levels as described previously (41, 42). Expression of lactoperoxidase and Duox1 was low preterm, at gestational days 115 and 130, and at birth, while expression was markedly increased in adults ( Figure 5A and 5B). Expression of Duox2 was increased at day 115 of gestation, decreased progressively with gestational age, and was also markedly increased in adults ( Figure 5C ). These data indicate that Duox1, Duox2, and LPO are expressed in the airways of newborn lambs albeit at lower levels than in adult sheep. DISCUSSION Viral respiratory tract infections are common and can be life threatening and there are no fully effective therapies or approved vaccines. Overall our findings indicate that the use of high-dose KI supplementation in vivo lessens the severity of RSV infections in newborn and 3-week-old lambs, through the augmentation of mucosal oxidative defenses.
There are several animal models of RSV infection and each has unique features. Lambs, like infants, have submucosal glands which produce LPO and also express sufficient levels of Dual oxidases and halide transport systems (23, 24) to support formation of the pseudohypohalide OSCN -or, in the presence of sufficient I -, HOI.
Rodents lack significant submucosal gland formation in the intrapulmonary airways and thereby also lack sufficient LPO production for a fully functional oxidative defense system within the airways (31) . In addition, lambs are susceptible to infection by several strains of RSV, including hRSV M37 used in this study (27, 28- Newborn lambs receiving KI exhibited reduced levels of expiratory effort, gross lesions, RSV antigen distribution, and a trend of reduced RSV N gene mRNA levels. KI treatment in the older, 3-week-old lambs was associated with reduced RSV titers in BALF along with reduced RSV antigen load by immunohistochemistry, and reduced RSV nucleoprotein mRNA levels by RT-qPCR. Microscopic lesions (consolidation scores) were not significantly reduced with KI treatment in either newborn or 3-week-old lambs, although there was a trend towards reduced lesions in the 3-week-old lambs. Thus, while not all measured parameters of RSV infection were altered by KI treatment, reductions in viral parameters (e.g., viral titer, antigen, and RNA levels) and clinical features (reduced expiratory effort) are of particular significance in lessening RSV disease severity. Mechanistically, administration of Dapsone with RSV and KI in newborn lambs reversed the effects of the KI treated and resulted in disease severity equal to and often significantly greater than M37 alone (no KI or Dapsone). HOI and/or hypoiodite (OI -) production is very difficult to measure in vivo because such reactive oxygen species have very short molecular half-lives in general (12, 14) . Thus, the extent to which HOI -was formed in the ASL of the KI-treated lambs in this study is not known. However, because Dapsone inhibits lactoperoxidase (LPO) and LPO is essential for catalyzing the reaction of KI and H 2 O 2 to HOI, these findings suggest that: 1) the Duox/LPO system is essential to the anti-RSV activity seen in these studies and 2) KI itself is not sufficient for the anti-RSV activity.
These findings are consistent with in vivo studies that demonstrated significant anti-RSV activity by HOI and a lack of direct RSV killing by KI, LPO, or H 2 O 2 individually (24) . Dapsone has been used previously in sheep to inhibit LPO activity which allowed increased colonization by a Gram-negative bacterial pathogen in the respiratory tract (23) . Also, lambs in this study demonstrated high ASL [I -] levels when receiving daily KI. It is also possible that there are other non-oxidative properties of KI that result in anti-RSV activity, such as its efficacy as an expectorant agent (43) but expectorants are generally not effective in reducing RSV replication.
KI treatment reduced disease severity to a greater degree in 3-week-old lambs than in newborn lambs as reflected by the large reductions in titer, antigen, and viral mRNA levels (viral mRNA levels trended lower in KItreated 2-3 day old lambs were not significantly reduced despite a larger group number). While the reason for this is not fully understood, we speculate that the respiratory tracts of 3-week-old lambs are more mature and have more fully differentiated epithelia than newborns and, therefore, have more available Duox/LPO expression and activity to convert KI to HOI than do newborn lambs. Alternatively, we have shown previously that younger lambs (especially preterm) exhibit increased disease severity compared to older lambs. Therefore, it could be that RSV disease severity was slightly less in the 3-week-old lambs as reflected by their lack of increased expiratory effort compared to the markedly enhanced expiratory efforts observed in the younger lambs. Thus, if RSV disease severity is less in older lambs than newborn, the effects of KI treatment may appear more pronounced in older lambs. It is also possible that older lambs may have enhanced innate and adaptive immune responses that synergize with KI treatment.
KI was delivered prophylactically in this study and thus, iodide levels in the ASL were high at the time of RSV nebulization. Because of this, it was suspected that nebulized particles would come into contact with HOI present on the ASL -inhibiting initial RSV attachment and infection. However, while prophylactic administration of KI reduced many parameters of RSV infection and RSV disease severity, it did not completely prevent RSV infection; since KI-treated lambs developed some gross and histologic lesions, and viral RNA and antigen were present (albeit at significantly reduced levels) compared to untreated animals. It is possible that not all RSV virions were inactivated upon initial contact with the respiratory mucosa during nebulization. More specifically, it is likely that HOI levels are higher in the nasal mucosa, trachea and bronchi, all three of which are anatomical locations where submucosal glands (and LPO) are present, than in the distal bronchioles and alveoli (both lacking in submucosal glands). Thus, nebulized virions deposited onto the upper airways may be damaged/destroyed by HOI whereas those virions deposited onto bronchioles or alveoli may have evaded HOI.
Deposition and infection by RSV at these distal locations may allow some level of viral infection since the distal bronchioles and alveoli are important sites of RSV replication. In other words, there may be a mismatch between sites of HOI production and some areas of the airways and alveoli that are susceptible to RSV infection.
Because KI was delivered daily after initial infection, it is also possible that HOI has effects on RSV virions produced in the lung after RSV nebulization. KI treatment may impair/damage virus released from respiratory mucosa during replication cycles several days after inoculation of RSV. Prophylactic protection by KI, as demonstrated in this study, might be effective in preventing spread of RSV to non-infected individuals treated with KI. It is also possible that KI treatment might have some beneficial effect in individuals already infected with RSV. Further studies are needed to optimize KI as a therapeutic, including determining its effectiveness with different routes of infection (intratracheal, intrabronchial, or aerosolized RSV), activity against different viral and bacterial pathogens, optimizing the dose and timing of KI administration, and the effects of inhibition of various components of the Duox/LPO/halide system.
In a previous study, we showed that the [I -] increased in the upper airway secretions of human subjects following oral intake of KI (24) . In the current study, through the use of the lamb model, we determined that I -was secreted not only in the upper airways, but also in the trachea following I -supplementation. In both humans and lambs, the [I -] was found to be more than 20-fold higher in ASL than in serum. The mechanism responsible for secretion of I -in the airways is not known. Fragoso and colleagues have reported that the sodium-iodide symporter (NIS) is expressed in the submucosal glands of airways where it is localized to the basolateral membrane of epithelial cells (16) . On the apical side of the epithelium, I -may be exported through I -permeable ion channels or anion transporters. Among the apical anion channels of airway epithelia, Ca 2+ -activated Cl -channels and the cystic fibrosis transmembrane conductance regulator (CFTR) are known to be I -permeable (44). Furthermore, the anion transporter, pendrin, has been detected in the apical membrane of airway epithelial cells (20) . NIS, CFTR, Ca 2+ -activated Cl -channels, and pendrin have also been implicated in the secretion of SCN -. The fact that the increased ASL [I -] is accompanied by reduced SCN -levels supports the notion that the same ion transporters are involved in both SCN -and I -secretion in the airways.
Previous studies have shown that lambs express all components of this mucosal oxidative defense system at levels sufficient for activity in the airways (23), and our results indicate that prophylactic administration of KI reduces RSV disease severity. These findings have implications for use of KI in infants against RSV or other respiratory pathogens since KI is relatively inexpensive, stable, can be readily transported, and does not require refrigeration or specialized storage. The extent to which KI treatment may reduce RSV disease severity in preterm and premature lambs and in lambs was not assessed in this study. RSV disease in humans often occurs in infants born prematurely and therapies are needed, but additional studies will be required in order to better understand the ontogeny and activity of the components of the Duox/LPO/halide host defense system in the preterm lung. Overall our findings indicate that the use of high-dose KI supplementation in vivo lessens the severity of RSV infections, potentially through the augmentation of mucosal oxidative defenses. McCray Jr., Mark R. Ackermann Table 1 . RT-qPCR primers and hydrolysis probes used in this study. 
MATERIALS AND METHODS

Lamb RSV challenge experiments (methods continued from text).
In the 2-3 day old lambs and 3-week-old lambs, each of the 3 groups of lambs contained 6 animals, and the experiment was carried out twice in 2-3 day-old (newborn) lambs (n = 12 in each treatment group) and once in an additional group (n = 5 lambs) that received daily administration and clinical severity of RSV disease for each lamb was assessed daily and scored as described (28, (33) (34) (35) (36) ; increased expiratory effort (also termed forced expiration) was scored blindly daily as: 0 = no increased effort; 1 = earliest detectable; 2 = moderate (>1 sec) with some abdominal effort; 3 = marked (>3 sec) with hard abdominal effort. Lambs were euthanized by sodium pentobarbital overdose on day 6 post-inoculation when RSV-induced lesions are maximal in this model (28, (33) (34) (35) (36) . During the RSV challenge experiments, lambs received a custom diet (Milk Products Inc., Chilton, WI, USA) that lacked supplemental I -and the lack of I -in this diet was verified in our laboratory using anion-exchange chromatography as previously described (24, 32) .
All animal experiments were approved by the Institutional Animal Care and Use Committee (IACUC) of Iowa State University.
Post-mortem analysis of RSV disease severity.
The thoraxes of euthanized lambs were opened, lungs photographed in situ and ex vivo, and gross lesions were scored as described previously (28, (33) (34) (35) (36) . Multiple samples from each lung lobe were collected and processed for RNA isolation as described previously (28, (33) (34) (35) (36) (37) (38) (39) (40) (41) . The isolated RNA was assessed for quality (supplemental figure E1 ) and used for RT-qPCR analysis of the expressions of RSV nucleoprotein (N gene) mRNA, immune and inflammatory gene mRNAs according to the PREXCEL-Q Method (30-33, see protocol, below). Primers and probes were designed using ABI Primer Express 2.0 (see oligo sequences in supplemental Table 1 ).
Two additional samples from each lobe were fixed in 10% neutral-buffered formalin, embedded into paraffin, sectioned, stained with H & E, and assessed by light microscopy for lung lesions as described previously (28, (33) (34) (35) (36) . Briefly, a 4-point scale was used to describe the percentage involvement of lung parenchyma: 0% consolidation = 0, 1-9% consolidation = 1, 10-39% consolidation = 2, 40-69% consolidation = 3, 70-100% consolidation = 4. Other formalin-fixed paraffin-embedded (FFPE) sections of the lung lobes were used for the immunohistochemical detection of RSV antigen expression, and the expression of RSV antigen was scored as described previously (25, (30) (31) (32) (33) , see more details below).
In addition to the lung collected for RNA isolation and histological samples, bronchoalveolar lavage fluid (BALF) was also collected from each 3-week-old lamb and used for the determination of viral titers and cytology (see details in the online data supplement). Briefly, the right caudal lung lobe was flushed through a major bronchus with 5 ml of cold modified Iscove's media (containing 42.5% Iscove's modified Dulbecco's medium, 7.5% glycerol, 1% heat-inactivated FBS, 49% DMEM, and 5 µg/ml kanamycin sulfate), and 1 ml of the collected BALF was used for infectious focus assay (see detailed protocol in the online data supplement). BALF was also collected from the accessory lobe by flushing the lobe through its major bronchus with 1 ml sterile PBS. These BALF samples were analyzed for total nucleated cell count and differential cell count by a board certified veterinary clinical pathologist blinded to the identity of individual samples (see details of the cytology method in the online data supplement). In some BALF samples, too few intact nucleated cells were present to perform a differential cell count; these samples were excluded from the statistical analysis.
Effect of Dapsone on RSV in vitro
The extent to which dapsone may have anti-RSV activity was assessed in vitro. HEp Ontologic expression of Duox1, Duox2, and LPO genes in lamb lung.
The extent to which Duox1, Duox2, and LPO mRNA are expressed in the lung during development was assessed by RT-qPCR using lung RNA from lambs at various developmental time points:
115 days gestation (n = 5), 130 days gestation (n = 4), at birth (n =4) and adults (n = 4) as described previously (41, 42).
Infectious focus assay used on collected BALF samples.
BALF was collected as described above, and 1 ml samples from each lamb were tested for the presence of live virus by an infectious focus assay. Briefly, HEp-2 cells were grown to 70% confluence in 12-well culture plates (Fisher Scientific, Hanover, IL, USA) in DMEM media (Mediatech, Inc., Manassas, VA, USA) supplemented to 10% with heat-inactivated fetal bovine serum (FBS) (Atlanta Biologicals, Atlanta, GA, USA) and 50 g/ml kanamycin sulfate (Invitrogen).
Each sample was analyzed at full-strength and at four additional serial-dilutions of 10-fold, 100-fold, 1,000-fold and 10,000-fold. 200 l of each BALF sample dilution was added in duplicate to wells of a 12-well plate (e.g., each BALF sample used an entire 12-well culture plate); two control wells on each plate received virus-free cell culture medium. Plates were incubated for 80 minutes in a CO 2 incubator at 37°C and 5% CO 2 with manual rocking every 20 minutes. 1 ml of culture medium was added to each well and plates were allowed to incubate for 48 hours after which medium was removed from all wells and cells in all wells were immediately fixed with 60% acetone/40% methanol solution for 1 minute. The acetone/methanol was removed and plates were allowed to air dry for about 2 minutes after which each well was rehydrated with 1 ml TBS-0.05% Tween 20, pH 7.4-7.6 (TBS-tw) for 1 minute with mild rotation. To block non-specific binding, 1 ml of 3% BSA (Fisher Scientific) in TBS-tw was added to all wells at room temperature for 30 minutes with gentle rocking. Primary antibody (MAb to RSV Fusion Protein, Clone: RSV 3216 (B016), Meridian Bioscience, Cincinnati, OH, USA) was diluted 1:800 in TBS-tw containing 3% BSA; 325l of this was added to each well and plates were allowed to incubate overnight at 4°C with gentle rocking. In the morning, plates were washed gently three times for 5 minutes each with TBS-tw, then 325l secondary antibody (Goat anti-Mouse Fab' conjugated to
Bronchoalveolar lavage fluid (BALF) cytology.
Aliquots of BALF (obtained from each lamb by pipetting 1 ml sterile PBS, pH 7.4 into the major bronchus of the accessory lobe and recovering 500 l of fluid) were submitted to the clinical pathology laboratory (Iowa State University, College of Veterinary Medicine) for measurement of total nucleated cell count and cytology slide preparation. Cell counts were performed on a ADVIA 120™ automated hematology analyzer (samples were diluted 2-fold in isotonic saline prior to cell counts due to low sample volumes). Cytospin preparations of BALF were created using a Shandon Cytospin 3 set at 800 rpm (spun for 10 minutes with low acceleration). Slides were stained with modified Wright's using a Hematek automated stainer. Differential cell counts (based on a 300 cell differential) were performed by a board certified veterinary clinical pathologist blinded to the identity of individual samples. In some BALF samples, too few intact nucleated cells were present on the cytospin samples to perform a 300 cell differential; therefore, these samples were excluded from the final analysis.
Statistical Analysis.
All analyses were performed using GraphPad Prism 6 (GraphPad Software Inc, La Jolla, CA). All post-mortem data was assessed by one-way ANOVA followed by Tukey's post-test. All clinical data were assessed by two-way ANOVA, and cumulative weight change was additionally assessed by one-way ANOVA followed by Tukey's post-test. Control group n = 10; M37 group n = 16; M37+KI group n = 14. Error bars = SEM, *p<0.05. Figure E4 . Effect of KI on mRNA levels of immune and inflammatory genes six days following initial virus inoculation in 3-week-old lambs. Messenger RNA levels of IFN, IL-8 and RANTES
were reduced (IFN significantly) by KI treatment; whereas IL-10, TGFβ, and MIP1α were significantly increased. Control group n = 4; M37 group n = 5; M37+KI group n = 5. Error bars = SEM, ***p<0.001, **p<0.01, *p<0.05. 
